psalexa
P&S Market Research - A market research firm

Anaplastic Oligoastrocytoma Therapeutics Pipeline Analysis

Anaplastic Oligoastrocytoma Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Delivery : 1-2 Working Days
Report Code: LS11215
Available Format:

Anaplastic oligoastrocytoma is a type of brain tumour in which certain brain cells such as oligodendrocytes and astrocytes, rapidly increase in number and form a mass. The disease is also called mixed glioma because it involves two types of cells. Anaplastic oligoastrocytoma generally occurs in the cerebrum region. Some of the symptoms of anaplastic oligoastrocytoma include seizures, headache and change in personality. The disease can be treated by surgical methods that involve removal of the tumour. A combination of chemotherapy and radiation therapy is also required for further destruction of cancer cells. Ziopharm Oncology, Inc. is in the process of developing INXN-2001 as a gene therapy for the treatment of anaplastic oligoastrocytoma. The Sun Yat-sen University is in the process of developing β-elemene as an anti-tumour agent for the treatment of anaplastic oligoastrocytoma. Some of the companies and universities having the pipeline of anaplastic oligoastrocytoma include Novartis AG, Northwestern University, and others.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 3250
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 4000
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry